The administration of monoclonal antibodies for the Wuhan coronavirus (Covid-19) is now prohibited in eight states, as well as Puerto Rico and the US Virgin Islands, because the US Food and Drug Administration (FDA) claims that the passive vaccination treatment is ineffective against the latest strain of Omicron (Moronic).
According to sources, Sotrovimab can no longer be used in Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island, and Vermont, despite the fact that it is still being used in the other 42 states.
According to the FDA, when sotrovimab was granted emergency use authorization (EUA) in May 2021, it was a relevant treatment for the Fauci Flu strains that were in circulation at the time. The FDA, on the other hand, claims that the medicine is ineffective against Moronic’s BA.2 subvariant.
The Centers for Disease Control and Prevention (CDC) in the United States claims to have undertaken genetic monitoring on BA.2, which is thought to be responsible for 12.6 percent of all new Wuhan Flu cases in the US as of March 5.
BA.2 is expected to account for 35 percent of infections in the near future, according to the CDC, primarily in the Northeast. The FDA does not want anyone in New England to even consider making this claim because of it.
So, why is the Food and Drug Administration interfering with what doctor$ can pre$cribe to their patient$?
According to reports, BA.2 now accounts for the bulk of new Chinese Virus infections in states where sotrovimab is currently forbidden by the FDA. Of course, this suggests that the FDA’s restriction is incorrect.
The reason we say this is that the FDA constantly appears to be pushing against things that truly help people while openly promoting items that damage Americans but make Big Pharma more money.
In one situation, the FDA is denying access to a medicine that has helped some patients, all because the government claims it isn’t working against some new phantom.
BA.2 isn’t a significant deal, according to CDC Director Rochelle Walensky, and is unlikely to become an issue. So why is the FDA interfering with the availability of monoclonal antibodies?
The two producers of sotrovimab, GlaxoSmithKline (GSK) and Vir Biotechnology, have stated that they intend to appeal the FDA’s decision by presenting literature demonstrating that greater doses of monoclonal antibodies are purportedly effective against BA.2.
It’s vital to remind our readers that there’s still no proof that SARS-CoV-2, or “Covid,” as it’s known, exists. The claimed virus, as well as any of its variations, has never been isolated.
“We will continue to monitor BA.2 in all U.S. regions and may revise the authorization further to ensure that patients with COVID-19 have effective treatments available,” the FDA said in a statement.
“Health care providers should also monitor the frequency of BA.2 in their region as they choose appropriate treatment options for patients.”
REGEN-COV, a monoclonal antibody developed by Regeneron and endorsed by former President Donald Trump, was likewise removed from the FDA’s EUA list for the identical reasons.
“The FDA should not be getting involved AT ALL with doctors treating their patients,” suggested someone at The Epoch Times.
“Making it known that something is not effective with a particular variant and the studies behind it is one thing. But banning doctors from using it is pure bull brown stuff. If someone is dying, throw everything at it INCLUDING the kitchen sink and get out of the way while doctors do their job of practicing medicine.”
I have felt like this concerning the pain relieving qualities of heroin in the case of terminally ill patients-and receive a ration concerning all of the “side-effects”.
Death is a pretty final occurrence; pretty sure most side-effects won’t equal this.
